La mesure de la clarté nucale et le dosage des marqueurs sériques commencent-ils à modifier l'incidence de la trisomie 21 en France ?

This publication has 12 references indexed in Scilit:

• Antenatal screening for Down's syndrome with the quadruple test
  The Lancet, 2003
• Combined second-trimester biochemical and ultrasound screening for Down syndrome
  Obstetrics & Gynecology, 2002
• Risk of amniocentesis in women screened positive for Down syndrome with second trimester maternal serum markers
  Prenatal Diagnosis, 2002
• Mothers’ knowledge of screening for trisomy 21 in 1999: a survey in Paris maternity units
  European Journal of Obstetrics & Gynecology and Reproductive Biology, 2002
• One stop clinic for assessment of risk for fetal anomalies: a report of the first year of prospective screening for chromosomal anomalies in the first trimester
  BJOG: An International Journal of Obstetrics and Gynaecology, 2000
• First-Trimester down syndrome screening using dried blood biochemistry and nuchal translucency
  Obstetrics & Gynecology, 2000
• UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10–14 weeks of gestation
  The Lancet, 1998
• Screening for fetal trisomies by maternal age and fetal nuchal translucency thickness at 10 to 14 weeks of gestation
  BJOG: An International Journal of Obstetrics and Gynaecology, 1995
• Reducing the Need for Amniocentesis in Women 35 Years of Age or Older with Serum Markers for Screening
  New England Journal of Medicine, 1994
• Maternal serum screening for Down's syndrome in early pregnancy.
  BMJ, 1988